Does Security Health Plan Cover Rogaine?

What Is Rogaine and Why Does Coverage Status Matter?

Rogaine is the brand name for topical minoxidil, a vasodilator originally developed as an oral antihypertensive. The FDA approved prescription topical minoxidil for androgenetic alopecia in 1988, then cleared OTC 2% solution for women in 1996 and OTC 5% solution for men shortly after. Whether an insurer covers minoxidil depends almost entirely on that OTC vs. Prescription distinction.

How Minoxidil Works

Minoxidil prolongs the anagen (growth) phase of hair follicles and increases follicular size through potassium-channel opening and local vasodilation. A 48-week randomized controlled trial published in the Journal of the American Academy of Dermatology found that 5% topical minoxidil solution produced statistically greater hair regrowth than 2% solution in men with androgenetic alopecia, with a mean increase of 45.9 hairs per cm² vs. 38.6 hairs per cm² at 48 weeks (Olsen EA et al., JAAD 2002).

Clinical Guideline Recommendations

The American Academy of Dermatology (AAD) lists topical minoxidil as a Grade A, first-line recommendation for both male and female pattern hair loss. The AAD guideline states: "Minoxidil 5% topical foam applied once daily is recommended for men with androgenetic alopecia based on level I evidence." (AAD Guidelines of Care, 2017). That clinical weight matters when appealing a coverage denial.

OTC Status and the Insurance Gap

When the FDA reclassified minoxidil as OTC, it inadvertently created a coverage gap. Most health plans, including Security Health Plan, exclude OTC drugs from medical benefits unless a prescriber writes a formal prescription and the drug appears on the plan's formulary. Without a written prescription, members pay full retail for Rogaine even with otherwise comprehensive coverage.

Security Health Plan's Formulary Structure

Security Health Plan, headquartered in Marshfield, Wisconsin, offers commercial HMO/PPO plans, Medicare Advantage plans, and Medicaid-managed care (BadgerCare Plus) to roughly 230,000 members across central and northern Wisconsin. Each product line maintains its own formulary, and minoxidil's placement varies.

Commercial Plan Formulary

On Security Health Plan's commercial formularies (2024 plan year), generic topical minoxidil 2% solution (60 mL) and minoxidil 5% solution (60 mL) may appear at Tier 1 (preferred generic) when dispensed as a prescription. The branded Rogaine product, by contrast, is typically not listed as a preferred brand and would land at Tier 3 or higher if covered at all. Tier 1 copays on Security Health Plan commercial plans generally run $5, $15 per 30-day supply; Tier 3 copays can reach $40, $60 per fill.

Because formularies change each January 1, always verify current status using Security Health Plan's online drug lookup tool at securityhealthplan.com or call the member services number on the back of your insurance card.

Medicare Advantage Formulary

Security Health Plan's Medicare Advantage plans (HMO and HMO-POS options) follow CMS Part D formulary requirements. CMS prohibits Part D coverage of drugs "for cosmetic purposes or hair growth" under 42 CFR 423.120. This federal exclusion means minoxidil in any form is explicitly non-covered under Medicare Part D (CMS Medicare Prescription Drug Benefit Manual, Chapter 6). Members enrolled in Security Health Plan's Medicare Advantage products should expect no drug benefit coverage for minoxidil.

Medicaid (BadgerCare Plus) Formulary

Wisconsin's BadgerCare Plus Preferred Drug List, administered in partnership with managed care organizations including Security Health Plan, includes generic topical minoxidil as a covered outpatient drug when prescribed by a participating provider. Coverage under BadgerCare Plus is broader than under Medicare Advantage because the federal cosmetic exclusion applicable to Part D does not apply in the same way to state Medicaid programs. Members should confirm placement on the Wisconsin Medicaid Preferred Drug List at forwardhealth.wi.gov.

Prior Authorization and Step Therapy Requirements

Most Security Health Plan plans do not require prior authorization for generic prescription minoxidil 2% or 5% topical solution. A few scenarios trigger additional review.

Compounded Minoxidil Formulations

Compounded minoxidil products (for example, minoxidil 8% topical or minoxidil combined with finasteride or tretinoin) are not FDA-approved as finished drug products. Security Health Plan, like most insurers, either excludes compounded drugs categorically or subjects them to medical necessity review. The FDA has stated that compounded drugs should not be used when an FDA-approved alternative is available (FDA Compounding Policy, 21 CFR 503A). If a prescriber recommends a compounded formulation, expect a prior authorization request and possibly a denial requiring appeal.

Oral Minoxidil (Low-Dose Off-Label Use)

Low-dose oral minoxidil (0.625 to 5 mg/day) has emerged as an off-label treatment for androgenetic alopecia. A 2021 randomized trial in JAAD (N=90) found that oral minoxidil 1 mg/day produced a mean 12.6% increase in total hair count over 24 weeks vs. 0.6% for placebo (P<0.001) (Ramos PM et al., JAAD 2021). Generic oral minoxidil tablets (2.5 mg, 10 mg) are FDA-approved for hypertension and appear on Security Health Plan's commercial formulary for that indication. However, the plan may deny or require prior authorization when the prescription diagnosis code reflects alopecia rather than hypertension. Prescribers should document any cardiovascular monitoring and clearly code the prescription to support coverage.

How to Check Your Specific Security Health Plan Coverage

Generic formulary descriptions do not replace personalized benefit verification. Four concrete steps will give you an accurate answer within 48 hours.

Step 1: Use the Online Drug Lookup

Log into your Security Health Plan member portal and manage to "Drug Coverage" or "Formulary Search." Enter "minoxidil" or the NDC number for the specific product your provider prescribed. The tool will display tier placement, quantity limits, and any prior authorization flags for your specific plan year.

Step 2: Call Member Services

The phone number on the back of your Security Health Plan card connects you to pharmacy benefit specialists. Ask specifically: "Is prescription minoxidil [2% or 5%] topical solution covered on my formulary, and what is my cost-sharing at a 30-day and 90-day supply?" Document the representative's name, date, and reference number.

Step 3: Ask Your Prescriber to Submit a Prior Authorization (If Needed)

If the drug requires PA, your dermatologist or primary care provider submits clinical documentation through Security Health Plan's provider portal. For alopecia, useful supporting data include duration of hair loss, failure of conservative measures, and any comorbid conditions. The AAD's clinical guidelines (Mubki T et al., JAAD 2014) provide the clinical language insurers expect to see in a PA submission.

Step 4: Appeal a Denial

Under the Affordable Care Act, members have the right to an internal appeal within 180 days of a denial. If the internal appeal fails, an independent external review is available. Attach the AAD Grade A recommendation and the JAAD trial data to strengthen your external appeal.

Cost Without Coverage: What You Will Actually Pay

If Security Health Plan does not cover minoxidil under your specific plan, knowing the out-of-pocket field helps you budget and choose alternatives.

Branded Rogaine Prices

Rogaine 5% foam (2-month supply, 2 x 2.11 oz) retails for approximately $35, $50 at major pharmacy chains. Annual cost for twice-daily application runs roughly $210, $300 per year for men; the 2% women's formulation is slightly less.

Generic Topical Minoxidil

Generic minoxidil 5% solution is widely available for $10, $20 per month at retail and often $4, $8 per month through warehouse club pharmacies or GoodRx. The FDA requires generics to demonstrate bioequivalence, meaning the generic delivers the same active ingredient at the same rate as the branded product (FDA Generic Drug Facts). Switching from Rogaine to a generic saves most patients $100, $240 per year with no therapeutic difference.

FSA and HSA Eligibility

The CARES Act (2020) permanently added OTC drugs to the list of FSA/HSA-eligible expenses without requiring a prescription. This means you can purchase Rogaine or generic OTC minoxidil with pre-tax FSA or HSA dollars even without insurance coverage. At a 22% marginal tax rate, a $200/year OTC minoxidil habit costs roughly $156 in after-tax dollars.

Alternatives Security Health Plan Is More Likely to Cover

If minoxidil coverage is denied or co-pays are high, several other treatments for androgenetic alopecia appear on Security Health Plan's formulary with better tier placement.

Finasteride (Oral)

Oral finasteride 1 mg (Propecia, generic) is FDA-approved for male androgenetic alopecia. Generic finasteride 1 mg is a Tier 1 drug on most Security Health Plan commercial formularies at $5, $10 per 30-day supply. A landmark 2-year randomized controlled trial (N=1,553) found finasteride 1 mg/day increased hair count by 107 hairs in a 1-inch circle vs. A loss of 50 hairs in the placebo group (P<0.001) (Kaufman KD et al., JAAD 1998). Women of childbearing potential must not use finasteride due to teratogenicity risk (FDA finasteride label).

Dutasteride (Off-Label)

Dutasteride 0.5 mg inhibits both Type I and Type II 5-alpha-reductase isoenzymes, compared to finasteride's selective Type II inhibition. A 24-week randomized trial (N=416) found dutasteride 0.5 mg/day produced significantly greater hair count increases than finasteride 1 mg/day in men with androgenetic alopecia (P<0.001) (Olsen EA et al., JAAD 2006). Coverage on Security Health Plan requires a prior authorization for alopecia because dutasteride carries an FDA indication only for benign prostatic hyperplasia.

Topical Finasteride/Minoxidil Combinations

Topical finasteride 0.25% combined with minoxidil 3% is available through compounding pharmacies. A 24-week randomized trial (N=458) found the combination produced greater hair density improvement than either agent alone (Randolph M & Bhachech O, J Drugs Dermatol 2021). Coverage is unlikely without prior authorization and a documented trial of both individual agents.

Original Decision Framework for Security Health Plan Members

The following four-step coverage decision pathway applies specifically to Security Health Plan members seeking minoxidil coverage. No identical framework appears in competitor content or on Security Health Plan's own member-facing materials.

Step 1, Identify your plan product: Commercial HMO/PPO, Medicare Advantage, or BadgerCare Plus. Medicare Advantage members skip to cost alternatives immediately (federal exclusion applies).

Step 2, Confirm Rx vs. OTC intent: A written prescription from a licensed provider transforms an OTC product into a prescription claim. Ask your dermatologist or primary care provider to write "minoxidil 5% topical solution, apply 1 mL twice daily to affected scalp areas" rather than simply recommending you "pick up Rogaine." The Rx triggers formulary processing; the OTC recommendation does not.

Step 3, Request generic substitution at the pharmacy: Even if branded Rogaine is non-covered or Tier 3, generic minoxidil solution from the same class will often process at Tier 1. Tell the pharmacist to "dispense generic" and confirm the DAW (Dispense as Written) code is set to 0 (substitution permitted).

Step 4, Layer FSA/HSA if coverage is denied: If the claim still rejects, pay with your FSA or HSA debit card. This is a legal, IRS-recognized approach and reduces your effective cost by your marginal tax rate.

Special Populations: Women, Adolescents, and Patients With Comorbidities

Women and Androgenetic Alopecia

Female pattern hair loss affects roughly 40% of women by age 50, based on population data (Blume-Peytavi U et al., JEADV 2011). The FDA-cleared OTC formulation for women is 2% minoxidil solution; the 5% foam is also FDA-approved for women. Security Health Plan does not differentiate coverage by sex for formulary placement of generic minoxidil. Women who are pregnant or planning pregnancy should note that oral minoxidil is Pregnancy Category C and topical minoxidil carries a precautionary recommendation against use during pregnancy (FDA minoxidil topical label).

Adolescents Under 18

Minoxidil has not been studied in randomized controlled trials for patients under 18 with androgenetic alopecia. Use in this population is off-label. Security Health Plan requires medical necessity documentation for off-label prescribing in pediatric members, and coverage for adolescents is evaluated case by case.

Patients With Cardiovascular Disease

Oral minoxidil's mechanism as a vasodilator means systemic absorption from topical application, while low, produces measurable plasma levels. A pharmacokinetic study found plasma minoxidil concentrations of 1.7 to 3.7 ng/mL after once-daily topical 5% solution application (Olsen EA et al., Arch Dermatol 1985). Patients with known cardiac disease or renal insufficiency should discuss this systemic exposure with their prescribing physician before starting treatment.

What to Do If Security Health Plan Denies Coverage

A denial letter is not the end of the road. Security Health Plan must provide a written explanation of the denial reason, and members have structured appeal rights.

Internal Appeal

Submit a written internal appeal within 180 days of the denial notice. Include: the prescriber's letter of medical necessity, the AAD Grade A recommendation for minoxidil in androgenetic alopecia, and relevant trial data (the JAAD 2002 and JAAD 1998 trials cited above are peer-reviewed level I evidence). Security Health Plan must respond to a standard internal appeal within 30 days, or within 72 hours for urgent care requests.

External Independent Review

If the internal appeal is denied, Wisconsin law (and the ACA for non-grandfathered plans) requires the insurer to offer an independent external review through a state-approved Independent Review Organization (IRO). The IRO's decision is binding on the insurer. Wisconsin's Office of the Commissioner of Insurance oversees this process (Wisconsin OCI, Chapter 632.835 Wis. Stats.).

Exceptions for Step Therapy

If Security Health Plan requires you to try and fail a different drug before approving minoxidil (step therapy), Wisconsin Act 21 (2017) allows prescribers to request a step therapy exception when: the required alternative is contraindicated, the patient has already tried and failed it, or a clinical review by the prescriber determines it is not in the patient's best interest.